{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:49:51Z","timestamp":1779144591242,"version":"3.51.4"},"reference-count":71,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.2217\/14622416.7.4.587","type":"journal-article","created":{"date-parts":[[2006,6,5]],"date-time":"2006-06-05T15:29:45Z","timestamp":1149521385000},"page":"587-596","source":"Crossref","is-referenced-by-count":15,"title":["The Clinical Implications of Antiretroviral Pharmacogenomics"],"prefix":"10.1080","volume":"7","author":[{"given":"Julie","family":"Fox","sequence":"first","affiliation":[{"name":"St. Mary\u2018s Hospital, Clinical Trials Centre, Winston Churchill Wing, Division of Medicine, Imperial College London, Praed Street, LondonW2 1NY, UK."},{"name":"Department of HIV Medicine, Jefferiss Wing, St. Mary\u2018s Hospital, LondonW2 1NY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital, Department of HIV Medicine, St. Stephens Centre, London, SW10 9NH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[{"name":"St. Mary\u2018s Hospital, Clinical Trials Centre, Winston Churchill Wing, Division of Medicine, Imperial College London, Praed Street, LondonW2 1NY, UK."},{"name":"Department of HIV Medicine, Jefferiss Wing, St. Mary\u2018s Hospital, LondonW2 1NY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,6,5]]},"reference":[{"key":"e_1_3_1_3_1_1","first-page":"1","volume":"4","author":"Pozniak A","year":"2003","unstructured":"Pozniak A , GazzardB, AndersonJ et\u00a0al.: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med.4(Suppl. 1), 1\u201341 (2003).","journal-title":"HIV Med."},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000307"},{"key":"e_1_3_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80132-6"},{"key":"e_1_3_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85132-3"},{"key":"e_1_3_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07873-X"},{"key":"e_1_3_1_3_6_1","unstructured":"Reeves I FisherM ChurchillD: Clinical utility of HLA-B*5701testing in a UK clinic cohort. 13th Conference on Retroviruses and Opportunistic Infections. Denver CO USA Abstract 667a (2006)."},{"key":"e_1_3_1_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200406000-00002"},{"key":"e_1_3_1_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-002-0070-x"},{"key":"e_1_3_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200210180-00005"},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00017"},{"key":"e_1_3_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.191"},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(99)00295-4"},{"key":"e_1_3_1_3_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000180786.02930.a1"},{"key":"e_1_3_1_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(96)80091-8"},{"key":"e_1_3_1_3_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350000500301"},{"key":"e_1_3_1_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/12487"},{"key":"e_1_3_1_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00005"},{"key":"e_1_3_1_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04139-8"},{"key":"e_1_3_1_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00014"},{"key":"e_1_3_1_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki184"},{"key":"e_1_3_1_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200107000-00004"},{"key":"e_1_3_1_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1999.tb11662.x"},{"key":"e_1_3_1_3_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.130-137.2003"},{"key":"e_1_3_1_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.05.116"},{"key":"e_1_3_1_3_25_1","first-page":"2391","volume":"18","author":"Haas DW","year":"2004","unstructured":"Haas DW , RibaudoHJ, KimRB et\u00a0al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids18, 2391\u20132400 (2004).","journal-title":"Aids"},{"key":"e_1_3_1_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200501000-00001"},{"key":"e_1_3_1_3_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/429327"},{"key":"e_1_3_1_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000189797.03845.90"},{"key":"e_1_3_1_3_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00002"},{"key":"e_1_3_1_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg137"},{"key":"e_1_3_1_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07276-8"},{"key":"e_1_3_1_3_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350400900610"},{"key":"e_1_3_1_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200106000-00003"},{"key":"e_1_3_1_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.21.12022-12029.2004"},{"key":"e_1_3_1_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200404000-00017"},{"key":"e_1_3_1_3_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/088922203769232629"},{"key":"e_1_3_1_3_37_1","first-page":"1","article-title":"Drug binding to human \u03b11-acid glycoprotein in health and disease.","volume":"40","author":"Kremer JM","year":"1988","unstructured":"Kremer JM , WiltingJ, JanssenLH: Drug binding to human \u03b11-acid glycoprotein in health and disease.Pharmacol. Rev.40, 1\u201347 (1988).","journal-title":"Pharmacol. Rev."},{"key":"e_1_3_1_3_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.54.1.129"},{"key":"e_1_3_1_3_39_1","doi-asserted-by":"publisher","DOI":"10.4238\/vol1-1gmr010"},{"key":"e_1_3_1_3_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216371.76689.63"},{"key":"e_1_3_1_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199605000-00006"},{"key":"e_1_3_1_3_42_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.40.1.581"},{"key":"e_1_3_1_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.12.026"},{"key":"e_1_3_1_3_44_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0026-895X(24)13065-9","article-title":"Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium.","volume":"54","author":"Strassburg CP","year":"1998","unstructured":"Strassburg CP , NguyenN, MannsMP, TukeyRH: Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium.Mol. Pharmacol.54, 647\u2013654 (1998).","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_1_3_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.231140698"},{"key":"e_1_3_1_3_46_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.17.1732.52347"},{"key":"e_1_3_1_3_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.18193"},{"key":"e_1_3_1_3_48_1","doi-asserted-by":"publisher","DOI":"10.1086\/466531"},{"key":"e_1_3_1_3_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/499056"},{"key":"e_1_3_1_3_50_1","doi-asserted-by":"publisher","DOI":"10.1086\/429303"},{"key":"e_1_3_1_3_51_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.1.1.507"},{"key":"e_1_3_1_3_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118324"},{"key":"e_1_3_1_3_53_1","doi-asserted-by":"publisher","DOI":"10.1086\/429295"},{"key":"e_1_3_1_3_54_1","unstructured":"Arnedo M TaffeP FurrerH et\u00a0al.: Modeling the influence of polymorphisms of several genes involved in lipid metabolism on the risk of ART-associated dyslipidemia. 13th Conference on Retroviruses and Opportunistic Infections. Denver CO USA Abstract 764 (2006)."},{"key":"e_1_3_1_3_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030052"},{"key":"e_1_3_1_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.08.014"},{"key":"e_1_3_1_3_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5270.1955"},{"key":"e_1_3_1_3_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200203010-00013"},{"key":"e_1_3_1_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.05.009"},{"key":"e_1_3_1_3_60_1","article-title":"Aplaviroc clinical development suspended and vicriviroc naive study stopped by DSMB.","volume":"1","author":"Moyle G","year":"2005","unstructured":"Moyle G , LalezariJ: Aplaviroc clinical development suspended and vicriviroc naive study stopped by DSMB.J. Viral Entry1, 47 (2005).","journal-title":"J. Viral Entry"},{"key":"e_1_3_1_3_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.21.13239-13249.2005"},{"key":"e_1_3_1_3_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm992"},{"key":"e_1_3_1_3_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000409"},{"key":"e_1_3_1_3_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200310170-00003"},{"key":"e_1_3_1_3_65_1","unstructured":"Burger D la Porte CGL van der Ende ME Meisen WMAJ Koopmans PP: Gender-related differences in efavirenz pharmacokinetics. 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes France Abstract 3.6 (2003)."},{"key":"e_1_3_1_3_66_1","unstructured":"la Porte CGL BurgerD GyssensL SprengerH KoopmansPP: Gender differences in nevirapine pharmacokinetics fact or fiction? 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes France Abstract 3.1 (2003)."},{"key":"e_1_3_1_3_67_1","unstructured":"Gatti G de Pascalis CR de Luca A et\u00a0al.: Pedictors of amprenavir parameters of drug exposure in heavily pretreated HIV+ patients. 6th International Congress on Drug Therapy in HIV Infection. Glasgow UK Abstract P165 (2002)."},{"key":"e_1_3_1_3_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200201010-00014"},{"key":"e_1_3_1_3_69_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.6.592.34744"},{"key":"e_1_3_1_3_70_1","unstructured":"Rodrigues N ovoa P Barreiro P Rendon A Zahonero I Jimenez V Soriano V: The 3435C>T polymorphism at the P-glycoprotein gene correlates with reduced plasma levels of atazanavir and lower risk of hyperbilirubinemia. 45th Annual Conference on Antimocrobial Agents and Chemotherapy. Washington DC USA Abstract H-1897 (2005)."},{"key":"e_1_3_1_3_71_1","unstructured":"De Luca A Di Giambenedetto S Schwarz J et\u00a0al.: The effect of polymorphism of the MDR-1 gene on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected patients starting ART. 13th Conference on Retroviruses and Opportunistic Infections. Denver CO USA Abstract 766 (2006)."}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14622416.7.4.587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:43:09Z","timestamp":1736401389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14622416.7.4.587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.2217\/14622416.7.4.587"],"URL":"https:\/\/doi.org\/10.2217\/14622416.7.4.587","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}